Swiss biotech firm Actelion Pharmaceuticals (VTX:ATLN) reportedly rejected Johnson & Johnson‘s (NYSE:JNJ) 2nd takeover offer, sending it shares down -6% in afternoon trading yesterday. The 2 companies have been engaged in informal talks for 2 months, according to Reuters, and the latest offer was pegged at 250 Swiss francs per share.
J&J’s $270 billion bid for Actelion tempted shareholders, who would rather have the cash now than wait and bet on Actelion CEO Jean-Paul Clozel’s risky pipeline of therapeutics for rare diseases, 1 investor told the news service.
Get the full story at our sister site, Drug Delivery Business News
The post Actelion rejects J&J’s takeover offer appeared first on MassDevice.